Compare Hasbro, Inc. (HAS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs TG Therapeutics Inc — how do they compare? Hasbro, Inc. trades at $94.24 (market cap $13.05B), while TG Therapeutics Inc trades at $55.05 (market cap $8.16B). The key difference: Hasbro, Inc. is the larger of the two by market cap, and Hasbro, Inc. pays a 3.03% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and TG Therapeutics Inc for 15 Days on average.
| HAS | TGTX | |
|---|---|---|
Market Cap | $13.05B | $8.16B |
Volume | 1,207,655 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $59.06 |
52-Week Low | $70.95 | $26.94 |
Typical Hold Time | 97 Days | 15 Days |
Enterprise Value | $15.24B | $8.37B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $90.75, down 0.31% on the day, with strong technical momentum showing bullish moving average signals and key support at $90. The company demonstrates robust profitability with 64.41% gross margins and has beaten earnings estimates for three consecutive quarters, though 2025 showed a net loss of $322.4 million. Analyst consensus remains positive with a $107.60 price target and no sell ratings among 33 analysts.
Outlook remains constructive with projected 2026 revenue growth to $5.0B and net income of $794M, supported by Magic: The Gathering's strong performance. Key risks include high debt levels at 59.09% debt-to-asset ratio and competitive pressures in the toy industry. The stock offers 18.5% upside to consensus target with institutional ownership showing mixed positioning.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
